The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 30, 2008
Filed:
Jun. 09, 2003
Ira H. Pastan, Potomac, MD (US);
Satoshi Nagata, Rockville, MD (US);
Masanori Onda, Rockville, MD (US);
Yoshito Numata, Osaka, JP;
Kenneth Santora, Kensington, MD (US);
Richard Beers, Rockville, MD (US);
Robert Kreitman, Potomac, MD (US);
Abhishek Sinha, San Diego, CA (US);
Ira H. Pastan, Potomac, MD (US);
Satoshi Nagata, Rockville, MD (US);
Masanori Onda, Rockville, MD (US);
Yoshito Numata, Osaka, JP;
Kenneth Santora, Kensington, MD (US);
Richard Beers, Rockville, MD (US);
Robert Kreitman, Potomac, MD (US);
Abhishek Sinha, San Diego, CA (US);
Abstract
CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular 'stalk' of CD30 remains after cleavage of sCD30. The stalk provides an advantageous and previously unrecognized target for immunotoxins. The invention provides antibodies that bind to the CD30 stalk or to epitopes destroyed upon the cleavage of CD30 which results in the stalk. The invention further provides new anti-CD30 antibodies that form effective immunotoxins and are particularly suitable for making disulfide stabilized Fv ('dsFv')-immunoconjugates. The dsFv immunoconjugates can be used as reagents to label CD30-expressing cancer cells or to inhibit the growth of CD30-expressing cancer cells. Moreover, the invention provides anti-CD30 antibodies that activate complement-dependent cytotoxicity.